Evolving Needs and a Treatment Option for R/R Multiple Myeloma

Where does ZENBEXUS fit in the treatment conversation for patients with relapsed/refractory multiple myeloma?

Tony Wang, PharmD, JD, will walk through the data and details clinicians need to know—from how ZENBEXUS works compared with historical immunomodulatory drugs to efficacy with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd).

The discussion will also take a practical look at safety, including findings from the EXCALIBER-RRMM study and key information from the ZENBEXUS label.

In this session:

• Mechanism: How ZENBEXUS differs from historical immunomodulatory drugs
• Efficacy: What the ZD d combination data show
• Safety: What to know from EXCALIBER-RRMM and the ZENBEXUS label

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.